Adial Pharmaceuticals Inc Common Stock (ADIL)
Stock · NASDAQ · Health Care
$3.46as of 10/16/2026
Price chart
Active signals
ADIL Signal Track Record
How signals performed across all stocks →What ADIL's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Bollinger Band Breakdown | 21 | -8.4% | 29% | May 7, 2026 |
| Bollinger Band Breakout | 20 | -10.0% | 15% | August 18, 2026 |
| Volume Spike | 17 | +0.2% | 53% | September 18, 2026 |
| Any 20-session window (baseline) | -10.5% | 30% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ADIL
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. The company's lead product is AD04, a serotonin-3 antagonist, which is in Phase 3 clinical trials for the treatment of alcohol use disorder. It is also involved in the development of drug candidates for non-opioid pain reduction and oth…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 5
- Website
- www.adialpharma.com/
Fundamentals
- 1-day range
- $3.07$3.66
- Market cap
- $10.29M
- P/E (trailing)
- —
- P/E (forward)
- -0.47
- EPS (trailing)
- $-16.57
- Dividend yield
- —
- Beta
- -301.92
- Avg. volume
- 57.7K
Forecasts
3 analyst ratings
Adial Pharmaceuticals Inc Common Stock Competitors
Chosen by industry and closest market cap.
- ADILAdial Pharmaceuticals Inc Common Stock$3.49▲ 11.15%Market cap $10.29MP/E —$1.31$232.5
- TOVXTheriva Biologics Inc. Common Stock$0.21▲ 0.00%Market cap $10.32MP/E —$0.1628$0.8632
- BIVIBioVie Inc. Class A Common Stock$1.2▲ 6.19%Market cap $10.18MP/E —$0.82$3.79
- LSTALisata Therapeutics Inc. Common Stock$1.03▼ 3.74%Market cap $9.74MP/E —$0.98$5.07
- BFRGBullfrog AI Holdings Inc. Common Stock$0.513▼ 4.11%Market cap $10.96MP/E —$0.4251$1.96
- LNAILunai Bioworks Inc. Common Stock$0.68▼ 17.68%Market cap $10.97MP/E —$0.8757$13.28
- GDTCCytoMed Therapeutics Limited Ordinary Shares$0.88▲ 1.15%Market cap $9.50MP/E —$0.6801$3.68
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ADIL Adial Pharmaceuticals Inc Common Stock | $10.29M | — | $3.49 | ▲ 11.15% | $1.31$232.5 |
| TOVX Theriva Biologics Inc. Common Stock | $10.32M | — | $0.21 | ▲ 0.00% | $0.1628$0.8632 |
| BIVI BioVie Inc. Class A Common Stock | $10.18M | — | $1.2 | ▲ 6.19% | $0.82$3.79 |
| LSTA Lisata Therapeutics Inc. Common Stock | $9.74M | — | $1.03 | ▼ 3.74% | $0.98$5.07 |
| BFRG Bullfrog AI Holdings Inc. Common Stock | $10.96M | — | $0.513 | ▼ 4.11% | $0.4251$1.96 |
| LNAI Lunai Bioworks Inc. Common Stock | $10.97M | — | $0.68 | ▼ 17.68% | $0.8757$13.28 |
| GDTC CytoMed Therapeutics Limited Ordinary Shares | $9.50M | — | $0.88 | ▲ 1.15% | $0.6801$3.68 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Adial Pharmaceuticals Announces Inducement Grant under Nasdaq Listing Rule 5635(c)(4)Yahoo · 9/30/2026
- 12 Health Care Stocks Moving In Friday's Intraday SessionBenzinga · 9/11/2026
Insider Activity
Insider Actions →- Young Wendy B. · September 17, 2026 · Grant25.7K
- Coastlands Capital LP · July 16, 2026 · Buy1.2K @ $2.75
- Coastlands Capital LP · July 14, 2026 · Buy2.0K @ $2.65
- Coastlands Capital LP · July 10, 2026 · Buy1.7K @ $2.7
- Coastlands Capital LP · July 9, 2026 · Buy10.1K @ $2.79
- Coastlands Capital LP · June 29, 2026 · Buy25.0K @ $2.6
- Matt Davidson · June 12, 2026 · Grant232.4K
- Young Wendy B. · June 12, 2026 · Buy36.4K @ $2.75
- Matt Davidson · June 11, 2026 · Grant101
- Matt Davidson · June 11, 2026 · Grant1.8K
- Matt Davidson · June 11, 2026 · Grant3.4K
- Matt Davidson · June 11, 2026 · Grant61.6K
Institutional Ownership
March 31, 2026
- Total shares held
- 29.7K
- Total value held
- $53.1K
- Institutional holders
- 13
- Unknown24.2K
- Unknown1.9K
- Unknown1.4K
- Unknown1.1K
- Unknown542
- Unknown361
- Unknown50
- Unknown47
- Unknown15
- Unknown6
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 2, 2026
Adial Pharmaceuticals Announces Nasdaq Inducement Grant
Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.
Adial Pharmaceuticals Announces Nasdaq Inducement Grant. Adial Pharmaceuticals disclosed a new inducement grant in compliance with Nasdaq Listing Rule 5635(c)(4). This corporate action is relevant as it relates to the company's adherence to exchange listing requirements. The stock currently trades well below its 52-week high, with recent volume spikes observed alongside the announcement.